1. Home
  2. FORR vs CCCC Comparison

FORR vs CCCC Comparison

Compare FORR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forrester Research Inc.

FORR

Forrester Research Inc.

HOLD

Current Price

$7.14

Market Cap

131.7M

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.50

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FORR
CCCC
Founded
1983
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
131.7M
240.3M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
FORR
CCCC
Price
$7.14
$2.50
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.50
AVG Volume (30 Days)
97.2K
1.4M
Earning Date
10-30-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$403,871,000.00
$30,108,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.60
$1.09
52 Week High
$16.80
$4.70

Technical Indicators

Market Signals
Indicator
FORR
CCCC
Relative Strength Index (RSI) 45.89 49.03
Support Level $6.60 $2.50
Resistance Level $7.50 $2.69
Average True Range (ATR) 0.29 0.18
MACD 0.08 -0.01
Stochastic Oscillator 58.89 23.86

Price Performance

Historical Comparison
FORR
CCCC

About FORR Forrester Research Inc.

Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: